Related Experiment Videos
Glycoxidation and lipoxidation in atherogenesis
1Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.
Free Radical Biology & Medicine
|August 18, 2000
Summary
Atherosclerosis may stem from chemical reactions, not just oxidative stress. Inhibitors of advanced glycation end-products (AGEs) may also slow atherosclerosis by targeting related lipid reactions.
Area of Science:
- Biochemistry
- Pathology
- Vascular Biology
Background:
- Atherosclerosis is an age-related disease.
- Lipid peroxidation in the vascular wall generates reactive carbonyl species.
- These species lead to macrophage recruitment and protein modification by advanced lipoxidation end-products (ALEs).
Purpose of the Study:
- To investigate the role of nonenzymatic chemical reactions in atherosclerosis.
- To explore the contribution of advanced glycation end-products (AGEs) and ALEs to atherogenesis.
- To evaluate the potential of AGE inhibitors in treating atherosclerosis.
Main Methods:
- The study focuses on the chemical mechanisms underlying atherosclerosis.
- It examines the formation of ALEs and AGEs from lipid and carbohydrate modifications.
- It considers the efficacy of nucleophilic AGE inhibitors.
Main Results:
- Failure of homeostasis and increased lipids, not oxidative stress, drive reactive carbonyl precursor formation.
- ALEs and their precursors alter vascular wall structure and function.
- AGE inhibitors also trap lipid precursors, suggesting broader therapeutic potential.
Conclusions:
- Atherosclerosis pathogenesis involves nonenzymatic chemical reactions, particularly ALE formation.
- Increased AGEs in diabetes exacerbate atherosclerosis risk.
- AGE inhibitors like aminoguanidine and pyridoxamine show promise for treating atherosclerosis in diabetic and non-diabetic individuals.